Contact

CRO, regulatory, ingredients, ABCI — each enquiry type goes to a different team

At AriBnC, clinical CRO work, regulatory affairs (Korea MFDS, US FDA, Health Canada, EU), functional ingredients and joint research with ABCI (the AI-Bio Convergence Institute) are each handled by a different team. An enquiry takes six fields — company, country, contact, business email, enquiry type and a short outline. If you want a quote, open the project detail in the same form and add it there. First reply within two to five business days KST.

Send an enquiryinfo@aribnc.com+82-70-7462-9418

Send an enquiry

Six fields. Sending issues a reference number, and we reply within two to five business days (KST). If you want a quote, add the project detail below. If useful, we follow up with a 30-minute online or video call.

Share an outline only at this stage

What you send passes through this website to AriBnC's intake record and business mailbox (info@aribnc.com), processed by the processor named in section 2 of the privacy policy (Google LLC). Do not enter unpublished technical information, trade secrets, study-subject information or personal health information.

If the matter is confidential, the safest course is to meet us at the Yongin head office; from outside Korea we can arrange a video conference instead.

The forms on this page collect business contact details and project information only. Each consent is chosen separately, and none is pre-ticked.

Use the registered entity name. For universities and institutes, adding the department or centre speeds up routing.
Korea / Japan / China / United States / Canada / EU / India / Vietnam / other. Used to judge the regulatory route and the language we reply in.
Used only for how we address you. What is on your business card is enough.
A company domain address is preferred. It is the address we reply to.
CRO quote / regulatory advisory / ingredient supply / ABCI joint research / document or certificate request / press / something else. Pick the last one if none of the others fit. Choosing document request, press or something else removes the project detail from the form.
0 / 500Up to 500 characters. Only what you know so far is fine. For press enquiries, please add your deadline (KST). Do not enter personal health information or unpublished technical information.
Add project detail (optional)

Open this if you want a quote. Leaving it closed does not hold up your enquiry; the more you fill in, the fewer quoting rounds.

Material name, source, dosage form, content, purpose of use. If you cannot disclose yet, write "after NDA".
Target market and regulatory route
Tick every route that applies.
Nonclinical (in vitro bioactivity, in vivo mechanism, specification, marker compound, process and analytical method, safety review, regulatory R&D design and documents) / Clinical (running the human application study or trial: protocol, conduct, monitoring, data management, study report) / Regulatory (preparing the MFDS and other submissions and responding to deficiency letters) / Full-service (nonclinical – clinical – regulatory) / Functional service provider, FSP (only some of biostatistics, data management and EDC, monitoring, or regulatory writing) / not sure.
List only what exists and in what form — in vitro and animal studies, specifications, marker compound, analytical method, safety data. Do not enter result values here.
Your preferred start date and what your organisation can approve are enough to help our review.

Please send any attachments as a reply to the email we send you after receiving your enquiry.

We use the project information you send only to prepare a quote and review the scope.

Do not include personal health information or information that identifies a study subject in any material you send.

A member of our team will reply within two to five business days (KST).

Enquiry types

Each type needs different information and goes to a different team. Choose yours in the enquiry form.

CRO

Quote for a clinical or human application study

Quotes cover protocol, conduct, monitoring, data management and the study report for health functional food human application studies, drug trials (Phase 2 and 3) and exploratory or confirmatory device trials. Our track record covers exploratory and confirmatory device trials. Telling us which development stage you need to start from — nonclinical, clinical or regulatory — cuts the number of quoting rounds.

Request a CRO quoteRegulatory

Regulatory advisory, Korea and overseas

We scope and quote MFDS individual recognition submissions and deficiency responses, US FDA (GRAS, NDI), Health Canada NHP/NPN via NNHPD, and EU novel food (Reg. 2015/2283) and health claims (Reg. 1924/2006, EFSA). We have supported MFDS individual recognition ingredient applications and US NDI notifications.

Request regulatory adviceIngredients

Ingredient and supply enquiries

Ask about specifications, samples and supply terms for BCS-001F black cumin seed extract powder (Nigella sativa L., individually recognised ingredient in Korea, recognition no. 2025-3) and probiotic strains developed by natural adaptation and selection at our UNIST Research Institute (the UNIST site of our Corporate Affiliated Research Institute), whole-genome sequenced and deposited.

Ask about ingredientsABCI

Joint research and national R&D

For joint research or consortium participation with ABCI, the AI-Bio Convergence Institute established in April 2026. Current national work: a MOTIR industrial-innovation national R&D programme under a 30-month agreement signed June 2026. Two AI-related patent applications have been filed (KR 10-2025-0108178, KR 10-2026-0099786).

Ask about joint researchPress

Press and media

Put the outlet, your deadline in KST and your questions in the outline field. Figures you need to quote are checked internally before we reply.

Press enquiryDocuments

Request a document or certificate copy

For a certificate copy, due-diligence paperwork, or company verification documents.

Request documentsOther

Anything else

For anything the types above do not cover. We work out who should answer and route it.

Send an enquiry

Where we pick it up — described by development stage

Wherever a project starts, it is designed so the next stage follows from it.

  1. Nonclinical

    Nonclinical — cells and animals

    • In vitro activity, in vivo mechanism, and the design and oversight of safety and toxicology work
    • Specification, marker compound, manufacturing process and analytical method
    • Standards — ICH M3(R2), the OECD Principles of Good Laboratory Practice (GLP), and Korea's MFDS GLP regulation
  2. Clinical

    Clinical — studies in people

    • Health functional food human application studies, Phase 2/3 drug trials, and exploratory and confirmatory device trials
    • Protocol design, site selection, management and monitoring, data management, biostatistics and the study report
    • Standards — ICH E6(R3) GCP, ICH E8(R1), Korean GCP (KGCP) for drugs and medical devices, and ISO 14155:2020 for device investigations
  3. Regulatory

    Regulatory — dossier and response

    • MFDS (individual recognition, functional labelling, IND, devices), US FDA (GRAS, NDI), Health Canada's NNHPD (NHP, NPN), and the EU (novel food Reg. 2015/2283, health claims Reg. 1924/2006)
    • Establishing the requirements, assembling and writing the dossier, and responding to deficiency letters

Frequently asked questions

Do I get a reply if I only send the enquiry?

Yes. A member of our team will reply within two to five business days (KST). If the scope is unclear, we suggest a 30-minute call first. The project detail is optional and sharpens a quote; it is not a condition of a reply.

Is there a fee for reviewing my request?

There is no charge for receiving an enquiry, reading the project detail, reviewing scope or the first reply. From the point where separate work is needed — drafting a study design, a regulatory gap analysis — we set out the terms in writing before starting.

Can companies outside Korea contact you?

Yes. We work with companies in the US, Italy, India, China, Vietnam and elsewhere, and in September 2026 signed a CRO contract with a US company. We hold a D-U-N-S Number (Sep 2026), so we can complete overseas vendor-registration procedures that require entity verification. We communicate with overseas companies in English.

Do I apply to the university research support programme through this form?

No. Please see the programme's information page, or ask us in person when you visit.

Reaching us and visiting

Visits require an appointment. Let us know in advance, by phone or email, what you would like to discuss, and we will book a meeting room and the right person and tell you the date of your visit. Please note that, for security reasons, entry may be restricted without an appointment.

  • Head office and laboratory: 1F Cheongsol Building, 16-6 Eondong-ro 125beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, Republic of Korea
  • Tel +82-70-7462-9418 · Fax +82-31-281-3385 · Email info@aribnc.com
  • Business hours: weekdays 09:00–18:00 KST
The ground-floor entrance of the Cheongsol Building, where the Yongin head office is. The glass door carries “Welcome to AriBnC” and the company mark
The entrance is on the ground floor: follow the deck to the glass door with the AriBnC logo. The address is 1F Cheongsol Building, 16-6 Eondong-ro 125beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do.

Not sure yet where to start, or whether you need full service or only specific functions? We can help. Talk the whole scope through with us — from study design and clinical operations to regulatory affairs.

Send an enquiry